Characterization of Leading Dysregulated Plasma-Proteome Associated Genes in Patients with Gastro-Esophageal Cancers.

doi:10.21203/rs.3.rs-122077/v1

Download PDF

Research Article

Characterization of Leading Dysregulated Plasma-Proteome Associated Genes in Patients with Gastro-Esophageal Cancers.

https://doi.org/10.21203/rs.3.rs-122077/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 07 Apr, 2021

Read the published version in Scientific Reports →

You are reading this latest preprint version

Background: Gastro-esophageal cancers are one of the major causes of cancer-related death in the world. There is a need for novel biomarkers in the management of gastro-esophageal cancers to identify new therapeutic targets and to yield predictive response to the available therapies. Our study aims to identify leading genes that are dysregulated (upregulated or downregulated) in patients with gastro-esophageal cancers.

Methods: We examined gene expression data for those genes whose protein products can be detected in the plasma in 600 independent tumor samples and 46 matching normal tissue samples using the Cancer Genome Atlas (TCGA) to identify leading genes that are dysregulated in patients with gastro-esophageal cancers. Non-parametric Mann-Whitney-U test was used to evaluate differential expression of genes using a cut-off of P< 0.05.

Results: The comparison between tumors sample and healthy tissue showed BIRC5 (p=2.61 E-08), APOC2 (p=3.23E-08), CENPF (p=4.38E-08), STMN1 (p=5.74E-08), and HNRPC (p=8.21E-08) were the leading genes significantly overexpressed in esophageal cancer whereas CST1 (p=3.97 E-21), INHBA (p=9.22E-20), ACAN (p=1.08E-19), HSP90AB1 (p=2.62E-19), and HSPD1 (p=3.91E-19) were the leading genes that were overexpressed in stomach cancer. Conversely, C16orf89 (9.78E-08), AR (1.01E-07), CKB (1.17E-07), ADH1B (1.79E-07), and NCAM1 (2.15E-07) were the leading gene that were significantly downregulated in esophageal cancer whereas GPX3 (1.65E-19), CLEC3B (5.70E-19), CFD (5.68E-18), GSN (4.5IE-17), and CCL14 (1.12E-16) were significantly downregulated in stomach cancer. Furthermore, Stage-based examination showed stage-specific differential expression of various genes as well as stage-wise increasing or decreasing up-regulation or down-regulation of selected genes, respectively.

Conclusions: The present study identified leading upregulated and downregulated genes in gastro-esophageal cancers that can be detected in the plasma proteome. These genes have potential to become diagnostic and therapeutic biomarkers for early detection of cancer, recurrence following surgery and for development of targeted-treatment.

Cancer Biology

Epigenetics & Genomics

Biological Chemistry

Stomach cancer

esophageal cancer

gastroesophageal cancer

upregulated genes

downregulated genes

Cancers of the stomach and esophagus or gastro-esophageal (GE) cancers represent a highly aggressive disease and are one of the major causes of cancer-related death in the world. Stomach cancer is the fifth most common cancer and the third leading cause of cancer-related death worldwide. For example, in 2018, more than 1 million new cases of stomach cancer were diagnosed and about 783,000 people die from it (1). Likewise, esophageal cancer is the seventh most common cancer and the sixth leading cause of cancer-related death. Each year more than 500,000 new cases of esophageal cancer are diagnosed and about 509,000 people die from it (1). Despite improvements in surgical and radiation treatments and the availability of newer agents, the prognosis of patients with recurrent GE cancers remains very poor (2–4). The need for novel strategies to improve current therapy is therefore vital in the management of GE cancers.

It is well known that cancer development and progression are triggered by altered activities and dysregulated expression of genes that control cell proliferation and differentiation (5). Comparative assessment of genetic aberrations between cancerous and matched normal tissues control has facilitated identification of new biomarkers that may also serve as new therapeutics targets or predict various cancer-related outcomes. There are several known biomarkers that are associated with tumorigenesis or have prognostic and predictive values in patients with stomach and esophageal cancers (6–10). For example, approximately 20% of stomach and gastroesophageal junction cancers are associated with the amplification of the HER2 gene that is an important therapeutic target and predicts response to trastuzumab (8). Most biomarkers such as TP53 or CDH1, however, have limited therapeutic and predictive values and presence or absence of them does not alter treatment strategies (9). There is a strong unmet need for novel biomarkers in the management of GE cancers to identify new therapeutic targets and to yield predictive response to the available therapies.

We conducted this study by intersecting the gene expression profiles from The Cancer Genome Atlas (TCGA) with the plasma proteome databases to identify leading genes that are dysregulated (upregulated or downregulated) in patients with esophageal and stomach cancers (11,12). The purpose of these analyses is to identify differentially expressed novel tumor-specific genes that code for the plasma proteins and use this information to develop blood-based prognostic biomarker studies in the near future.

TCGA Gene expression Analyses

We obtained the level-3 HiSeq RSEM gene-normalized RNA-seq gene expression data for stomach adenocarcinoma (STAD) and esophageal carcinoma (ESCA) from the TCGA database (11). Overall, gene expression data for 415 independent tumor samples and 35 matching normal tissue samples for STAD and for 185 ESCA cases with 11 matching normal tissue samples were available. We also downloaded the plasma proteome database from http://www.plasmaproteomedatabase.org. The database contained information on 1241 protein-coding genes, while gene expression profiles from TCGA mapped to 1232 protein-coding genes. To analyse plasma proteome genes, we used non-parametric Mann-Whitney-U test to identify genes that are expressed at significantly different levels (p < 0.05) in cancerous and normal tissues. The deregulated genes were grouped according to tumor stages based on the available patient data. This allowed identification of genes with expression significantly increased or decreased at multiple stages of cancer.

Leading upregulated genes in GE cancers

We examined gene expression of 1232 protein-coding genes that are detected in plasm proteome in tumors of 185 patients with esophageal cancer and in the matching tissue of 11 subjects with no cancer. Among cancer patients, 18 (9.7%) had stage I tumors, 78 (42.2%) had stage II disease, 56 (30.3%) had stage III disease, and 9 (4.9%) had stage IV cancer. In 24 (13%) patients, cancer stage was not known. The comparison between esophageal tumors and healthy tissue showed BIRC5 (p = 2.61 E-08), APOC2 (p = 3.23E-08), CENPF (p = 4.38E-08), STMN1 (p = 5.74E-08), and HNRPC (p = 8.21E-08) to be five leading genes overexpressed in esophageal cancer (Fig. 1A). The stage-based assessment of overexpressed genes showed significant overexpression of BIRC5, APOC2, CENPF, STMN1, and HNRPC across all cancer stages including early, locally advanced and metastatic esophageal tumors (Fig. 1B). The p-values for each gene compared to normal samples and number of samples in each stage are provided in supplementary table 1.

For stomach cancer, we evaluated 415 cases and compared them with 35 normal tissue samples. Among patients with stomach cancer, 57 (13.7%) had stage I cancer, 123 (29.6%) had stage II disease, 169 (40.7%) had stage III disease, and 41 (9.9%) had stage IV cancer. In 25 patients (6%) with stomach cancer, the disease stage was not known. Comparison between normal stomach tissue and stomach tumors showed that CST1 (p = 3.97 E-21), INHBA (p = 9.22E-20), ACAN (p = 1.08E-19), HSP90AB1 (p = 2.62E-19), and HSPD1 (p = 3.91E-19) were the leading five genes that were overexpressed in stomach cancer (Fig. 1C). The stage-based assessment of overexpressed genes showed significant upregulation of CST1, INHBA, ACAN, HSP90AB1, and HSPD1 genes across all stages, including early, locally advanced and metastatic stomach cancer (Fig. 1D). The p-values for each gene compared to normal samples and number of samples in each stage are provided in supplementary table 2.

Stage-specific upregulation of genes in GE Cancers

In this analysis we examined pattern of genes expression based on the specific-stage of the disease in GE cancers. In addition to the five overexpressed genes reported above, the stage-based analysis showed a differential expression of following genes based on the stage of the disease. Patients with stage I esophageal cancer have significantly higher expression of CPS1 (p = 0.003), PNP (p = 0.007), SERPINBB (p = 0.042) and EHD1 (p = 0.046). In patients with stage II disease, MSN (p = 0.003), KRTS (p = 0.004), TNC (p = 0.007), and NAP1L4 were overexpressed compared with other stages of the disease. In patients with stage IV esophageal cancer CYCS (p = 0.014), PON3 (p = 0.14), ACPP (p = 0.047), and RPL22 (p = 0.047) were significantly upregulated compared with patients with early stage cancer. We did not notice a stage-specific upregulated gene in stage III esophageal cancer (Fig. 2A). The p-values for each gene compared to normal samples are provided in supplementary table 3.

Likewise, the stage-based analysis in patients with stomach cancer showed a differential expression of several genes at the specific stages of the disease. Thus, patients with stage I, II, III, and IV stomach cancer have significantly higher overexpression of PYGB (p = 0.043), TNF (p = 0.02), HLA-A (0.05), and EFNB2 (0.001) genes, respectively (Fig. 2B). The p-values for each gene compared to normal samples are provided in supplementary table 4.

Stage-wise increasing overexpression of leading genes in GE cancers

In this analysis, we examined if certain genes expression intensifies in parallel with the progression of disease. The analysis showed a stage-wise increasing overexpression of ANGPT2, APOC2, CXCL5, HIST1H1E, IL17A, IL2RA, IL8, OSM, PFaV1, and SAA4 in esophageal cancer. Among them, a gradual increase from early stage cancer to more advanced stages was strongest for APOC2 and IL8 genes followed by for SAA4 and OSM genes, whereas HIST1H1E, PF4V1, CXCL5, and IL2RA expression showed limited stage-wise upregulation (Fig. 3A).

In the stomach cancer, the stage-wise analysis showed a gradual increasing overexpression of the following genes: AGRN, CETP, FGL1, HABP2, MDK, OSMR, RNASE2, SELE, SERPINE1, and VCAN. Among them, the upregulation from the early stage cancer to more advanced stages was the strongest for RNASE2, SERPINE1, and CETP (Fig. 3B).

Leading downregulated genes in GE cancers

In addition to the upregulated genes, we also examined leading downregulated genes that could play a major role in pathogenesis and progression of cancer. Our analysis showed that following five genes were most significantly downregulated in esophageal cancer: C16orf89 (9.78E-08), AR (1.01E-07), CKB (1.17E-07), ADH1B (1.79E-07), and NCAM1 (2.15E-07) (Fig. 4A). The stage-based analysis did not reveal the stage specific down-regulation. The stage-wise analysis showed a gradual downregulation of the following genes from stage I to IV esophageal cancer: AHNAK, APOM, ART3, CAMK2D, MB, MEGF8, MMRN1, PROC, S100A1, and TNFRSF10C (Fig. 4B).

In patients with stomach cancer following five genes were most significantly downregulated: GPX3 (1.65E-19), CLEC3B (5.70E-19), CFD (5.68E-18), GSN (4.5 IE-17), and CCL14 (1.12E-16) (Fig. 4C). The stage-based analysis showed that C1R (2.34E-04), A2M (3.15E-04), LTBP1 (3.15E-04), SERPING1 (4.23E-04), and BASP1 (4.88E-04) were significantly downregulated only in patients with stage I (early-stage) stomach cancer whereas SERPINB6 (2.0E-03), G0S2 (1.80E-02), HSD17B10 (2.50E-02), ECM1 (2.60E-02), and PRDX1 (2.80E-02) were significantly downregulated in patients with stage III (locally advanced) stomach cancer (Fig. 4D). The p-values for each gene compared to normal samples are provided in supplementary table 5. The stage-wise analysis revealed a progressive downregulation of the following genes from stage I to IV stomach cancer: ACAA1, AZGP1, BLVRB, CYB5A, EPHX2, FBP1, REG1A, SECTM1, SELENBP1, and TPPP3 (Figs. 4E and 4F). The p-values for each gene compared to normal samples are provided in supplementary table 6.

Our investigation discussed in this manuscript, allowed to characterize the leading genes that are upregulated or downregulated in patients with esophageal and stomach cancers. We specifically focussed on those genes whose protein products can be detected in the plasma, as measured in the plasma proteome database. Thus, our investigation has a direct translational impact. The abnormal gene expression plays a pivotal role in tumor development and progression (5). We noted that compared to normal tissue, BIRC5, CENPF, STMN1, APOC2, and HNRPC were the five most significantly upregulated genes in esophageal cancer. Furthermore, these genes were also overexpressed in stomach cancer.

The baculoviral IAP repeat containing 5 (BIRC5) gene, also known as survivin, is a member of the inhibitor of apoptosis (IAP) family, where genes encode regulatory proteins that prevent apoptotic cell death. Survivin localizes to the mitotic spindle and participates in regulating mitosis. In addition to GE cancers, it is highly expressed in various other malignancies and is associated with inferior outcomes including a shorter survival period (13–15). CENPF gene encodes centromere protein F that associates with the centromere-kinetochore complex. CENP-F protein is thought to be a cell cycle regulated protein that may play a role in chromosome segregation during mitosis. Interestingly, there is an evidence that CENPF expression is associated with inferior outcomes in patients with esophageal cancer and patients with lower CENPF expression had a better survival rate compared with those with higher CENPF expression (16). The CENPF gene is also amplified in other solid tumors including hepatocellular and breast cancers and correlates with patients’ outcomes (17–19). As cancer cells undergo active division, perhaps the up regulation of genes like BIRC5, CENPF could be a direct consequence of active mitosis.

STMN1 belongs to the stathmin family of genes and encodes a cytosoplasmic phosphoprotein stathmin 1. The encoded protein belongs to the family of microtubule-destabilizing proteins that control the assembly and disassembly of the mitotic spindle and thereby, regulate mitosis. Similar to esophageal cancer, STMN1 is highly expressed in various cancers, including leukemia, breast, prostate and lung cancer, and is a promising target for cancer therapy (20,21). There is some evidence that it may have a prognostic significance in the early stage gastric cancer. For example, a study that evaluated STMN1 role in both operable and advanced gastric cancers showed that in the operable cohort, STMN1 expression correlated with cancer recurrence, and resistance to adjuvant therapies (22).

In contrast to the relatively known roles of BIRC5, CENPF, and STMMN1 in malignancies, functions of APOC2 and HNRNPC genes in cancer cell are less well defined. The APOC2 gene encodes a lipid-binding protein that belongs to the apolipoprotein family and is a component of the very low-density lipoprotein. This protein activates the enzyme lipoprotein lipase, which hydrolyzes triglycerides. APOC2 mutations could cause hyperlipoproteinemia type IB, characterized by hypertriglyceridemia, xanthomas, and early atherosclerosis (23,24). HNRNPC gene encodes a protein that belongs to the subfamily of ubiquitously expressed heterogeneous nuclear ribonucleoproteins (hnRNPs). The hnRNPs are RNA binding proteins and are associated with pre-mRNAs in the nucleus. These proteins are involved in pre-mRNA processing and other aspects of mRNA metabolism and transport along with cell proliferation and differentiation (25). However, functions of hnRNPs in tumorigenesis and cancer progression in solid and hematological malignancies are not well understood (26).

Our analysis showed that compared with normal stomach tissue, CST1, INHBA, ACAN, HSP90AB1, and HSPD1 were the leading five genes that were overexpressed in stomach cancer. Furthermore, these genes were also upregulated in patients with esophageal cancer. The CST1 gene encodes a secretory peptide called Cystatin SN, which is a cysteine proteinase inhibitor. Cysteine proteases are involved in tissue remodeling during development, and they support the migration of cancer cells. CST1 itself is known to promote proliferation, clone formation, and metastasis in breast cancer cells and high CST1 expression is negatively correlated with breast cancer survival (27). CST1 has also been considered as a potential tumor marker in various epithelial malignancies (27,28). Of note, a study involving patients with esophageal squamous cell carcinoma whose tumors express high levels of Cystatin SN showed favorable survival compared with those patients with low Cystatin SN expression (29).

Inhibin-βA (INHBA), a ligand belonging to the transforming growth factor-β superfamily, is associated with cell proliferation in cancer. INHBA is overexpressed in various types of cancers including esophageal and stomach tumors (30,31). Overexpression of the INHBA gene is considered a useful independent predictor of outcomes in patients with gastric cancer after the curative surgery. High INHBA gene expression has shown to be associated with significantly poorer 5-year overall survival compared with low expression cases in patients with stomach cancer (31).

HSPD1 and HSP90AB1 belong to heath shock protein (HSP) group and encodechaperonin family proteins (32). HSPD1 encodes a mitochondrial protein, which is important for assembly of imported proteins in the mitochondria and may function as a signaling molecule in the immune system. HSP90AB1 is thought to play a role in gastric apoptosis and inflammation. HSPs control a wide variety of signaling and cellular responses and have been classified into several subfamilies such as the HSP60s, HSP70s, HSP90s, and HSP100s (33). HSP expression often correlates with patient prognosis in various malignancies (34–36) For example, HSP60 has been identified as an independent prognostic factor for both overall survival and recurrence-free survival in patients with early stage stomach cancer (36). The ACAN gene is a member of the aggrecan/versican proteoglycan family. The encoded protein is an integral part of the extracellular matrix in cartilagenous tissue and it withstands compression in cartilage. Mutations in this gene may be involved in skeletal dysplasia and spinal degeneration, however, its role in cancer is not well understood.

With respect to downregulated genes, C16orf89, AR, CKB, ADH1B, and NCAM1 were the leading downregulated genes in patients with esophageal cancer. C16orf89 is predominantly expressed in the thyroid gland and is involved in the development and function of the thyroid (37). Its role in tumorigenesis and progression has not been elucidated yet. The androgen-receptor (AR) gene encodes AR. Once AR binds its hormone ligand testosterone, it translocates into the nucleus, and stimulates transcription of androgen responsive genes (38). In vitro evidence suggests a significant influence of sex hormones upon cancer growth (38,39). For example, AR pathway plays an important role in the development of prostate cancer and various other epithelial malignancies including bladder, kidney, lung, breast, liver and ovary (39). However, AR role in GE cancers development and progression is not known (40). CKB or creatinine kinase B gene encodes a cytoplasmic enzyme that is involved in energy homeostasis. Its dysregulation could promote cancer invasiveness and progression (41). Similar to AR, its disease modulating effect in GE cancers is unknown. ADHIB encodes alcohol dehydrogenase 1B enzyme. Evidence suggests that genetic polymorphisms of this enzyme has been associated with the increased risk of the aerodigestive cancer triggered by alcohol consumption (42). The NCAM1or neural cell adhesion molecule 1 gene encodes a cell adhesion protein, a member of the immunoglobulin superfamily that is involved in both cell to cell and cell to matrix interactions. Its downregulation has been linked to cancer progression and development of metastases in gastrointestinal and other malignancies (43).

In patients with stomach cancers, GPX3, CLEC3B, CFD, GSN, and CCL14 were the leading five genes that were most significantly downregulated. GPX3 encodes glutathione peroxidase that belongs to a family of selenocysteine-containing redox enzymes that play important roles in cell signaling and immune modulation (44). Promoter hypermethylation and downregulation of Gpx3 in melanoma, stomach, head and neck, cervical and lung cancers suggest that Gpx3 serves as a tumor suppressor in these cancers (44,45). C-Type Lectin Domain Family 3 Member B (CLEC3B) is a member of the C-type lectin superfamily that encodes tetranectin. Dysregulation of CLEC3B has been reported in various epithelial cancers including stomach cancer (46,47). Chen and others using TCGA database also noted downregulation of CLEC3B in stomach cancer. However, when they evaluated 328 patients with early-stage stomach cancer, high intratumoral tetranectin level was significantly associated with tumor invasion, lymph node metastasis, advanced TNM stage, and a shorter overall survival (47). CFD or complement factor D encodes a serine protease that catalyze breakdown of factor B a rate limiting step of alternative pathway of complement activation. Impaired balance of complement activation could promote inflammation and tumorigenesis resulting in malignant cells proliferation, migration, invasiveness and metastasis (48,49). GSN or Gelsolin gene encodes a protein that is involved in assembly and disassembly of actin filaments. Gelsolin has been attributed in prostate tumorigenesis and malignant transformation (50,51). The C-C type chemokine 14 gene that encode the CC14 chemokine, which induces targeted cell migration is thought to play a role in carcinogenesis and metastasis of certain malignancies including breast cancer (52,53).

Aside from the leading upregulated and downregulated genes in patients with GE cancers, we also noted a stage-wise upregulation of several genes, such as APOC2, IL8, RNASE2, SERPINE1, and CETP, and stage-wise downregulation of other genes that play important role in and survival, including AHNAK, MEGF8, MMRN1, PROC, REG1A, SECTM1, TNFRSF10C, and TPPP3. The stage-related expression of these genes suggests their potential role in the disease progression and utility as monitoring markers or therapeutic targets. The cholesteryl ester transfer protein (CETP) for example maintains cholesterol homeostasis and has been identified as a potential target for estrogen positive breast cancer (54). Conversely, AHNAK can act as a tumour suppressor gene and mediates the negative regulation of cell growth (55)

While our work provides a significant amount of novel information regarding the behavior of cancer-related molecules in esophagus and stomach tumors, it does not assess the level of gene expression based on the molecular classification of stomach and esophageal cancers (7). Furthermore, we did not have information on histopathology of esophageal and stomach cancer available therefore, were not able to segregate the data based on histopathology.

In summary, the present study identified leading upregulated and downregulated genes in esophageal and stomach tumors. Since expression of the upregulated genes was minimal in both stomach and esophageal normal tissues, these genes have a strong potential to become diagnostic and therapeutic biomarkers for screening and early detection of cancer, recurrence following surgery and for anti-cancer therapies. Future studies will be required for validating diagnostic, therapeutic and prognostic importance of these genes. Our group plans to prospectively evaluate prognostic and predictive values of selected genes in a cohort of patients with metastatic gastroesophageal cancer who are treated with combination chemotherapy.

Acknowledgment

The study was supported by a research grant provided by the Saskatchewan Cancer Agency (Operating Grant) to FJV and SA.

Conflict of Interest

None of the authors have a conflict of interest to disclose in relationship with this research.

Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.

Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376:687.

Bouché O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study–FFCD 9803. J Clin Oncol 2004; 22:4319.

Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007; 25:3205.

Li M, Sun Q, Wang X. Transcriptional landscape of human cancers. Oncotarget. 2017; 8:34534–34551.

Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;12:169–175.

Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-9.

Chua TC, Merret ND. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes—a systematic review. Int J Cancer. 2012;130:2845–56.

Katona BW, Rustgi AK. Gastric Cancer Genomics: Advances and Future Directions. Cell Mol Gastroenterol Hepatol. 2017;3:211–217.

Liu X, Meltzer SJ. Gastric Cancer in the Era of Precision Medicine. Cell Mol Gastroenterol Hepatol. 2017;3:348–358.

National Cancer Institute GDC Data Portal https://portal.gdc.cancer.gov/ Accessed April 24, 2019.

Nanjappa V, Thomas JK, Marimuthu A, et al. Plasma Proteome Database as a resource for proteomics research: 2014 update. Nucleic Acids Res. 2013;42(Database issue):D959–D965.

Zhang S, Zhang C, Song Y, et al. Prognostic role of survivin in patients with glioma. Medicine. 2018; 97:e0571.

Gu Y, Li P, Peng F, Zhang M, et al: Autophagy-related prognostic signature for breast cancer. Mol Carcinog. 2016;55:292–299.

Shang X, Liu G, Zhang Y, et al. Downregulation of BIRC5 inhibits the migration and invasion of esophageal cancer cells by interacting with the PI3K/Akt signaling pathway. Oncol Lett. 2018;16:3373–3379.

Mi YJ, Gao J, Xie JD, et al. Prognostic relevance and therapeutic implications of centromere protein F expression in patients with esophageal squamous cell carcinoma. Dis Esophagus. 2013;26:636 − 43.

Kim HE Kim DG, Lee KJ, et al. Frequent amplification of CENPF, GMNN and CDK13 genes in hepatocellular carcinomas. PLoS One. 2012;7:e43223.

O'Brien SL, Fagan A, Fox EJ, et al. CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer. Int J Cancer 2007;120: 1434–1443.

Alli E, Yang JM, Hait WN. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53. Oncogene. 2007;26:1003–1012.

Bao P, Yokobori T, Altan B, et al. High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma. Ann Surg Oncol. 2017;24:4017–4024.

Ghosh R, Gu G, Tillman E, et al. Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression. Prostate. 2007;67:1038–1052.

Bai T, Yokobori T, Altan B, et al. High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancerpatients. British J Cancer 2017;116:1177–1185.

Surendran RP, Visser ME, Heemelaar S et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med. 2012;272:185 − 96.

Wolska A, Dunbar RL, Freeman LA, et al. Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism. Atherosclerosis. 2017; 267:49–60.

Hossain MN, Fuji M, Miki K, et al. Downregulation of hnRNP C1/C2 by siRNA sensitizes HeLa cells to various stresses. Mol. Cell. Biochem. 2007;296:151–157

Park YM, Hwang SJ, Kiyoshi Masuda K, et al. Heterogeneous Nuclear Ribonucleoprotein C1/C2 Controls the Metastatic Potential of Glioblastoma by Regulating PDCD4. Mol Cell Biol. 2012;32:4237–4244.

Dai D, Li Y, Chen B, et al. elevated expression of CST1 promotes breast cancer progression and predicts a poor prognosis. J Mol Med (Berl). 2017;95: 873–886

Jiang J, Liu HL, Liu ZH, et al. Identification of cystatin SN as a novel biomarker for pancreatic cancer. Tumour Biol. 2015;36:3903-10.

You-Fang Chen, Gang Ma, Xun Cao, et al. Overexpression of Cystatin SN positively affects survival of patients with surgically resected esophageal squamous cell carcinoma. BMC Surg 2013;13:15.

Seder et al. Hartojo W, Lin L, et al. INHBA Overexpression Promotes Cell Proliferation and May Be Epigenetically Regulated in Esophageal Adenocarcinoma. J Thorac Onc 2009;4:455 − 62.

Oshima T, Yoshihara K, Aoyama, T, et al Relation of INHBA Gene Expression to Outcomes in Gastric Cancer after Curative Surgery. Anticancer Res 2014;34: 2303–2310.

Bross P, Paula Fernandez-Guerra P. Disease-Associated Mutations in the HSPD1 Gene Encoding the Large Subunit of the Mitochondrial HSP60/HSP10 Chaperonin Complex. Front Mol Biosci. 2016;3:49.

Quintana FJ, Cohen IR. The HSP60 immune system network. Trends in immunology. 2011;32:89–95.

Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006;31: 164–172.

Campanella C, Rappa F, Sciume C. et al. Heat shock protein 60 levels in tissue and circulating exosomes in human large bowel cancer before and after ablative surgery. Cancer. 2015;121(18):3230–3239.

Li XS, Xu Q, Fu XY, et al. Heat shock protein 60 overexpression is associated with the progression and prognosis in gastric cancer. PloS one. 2014;9:e107507

Afink GB, Veenboer G, de Randamie J, et al. Initial characterization of C16orf89, a novel thyroid-specific gene. Thyroid. 2010;20:811 − 21.

Brooke GN, Bevan CL. The Role of Androgen Receptor Mutations in Prostate Cancer Progression Curr Genomics. 2009;10:18–25

Antonarakis ES. AR Signaling in Human Malignancies: Prostate Cancer and Beyond. Cancers (Basel). 2018;10:pii:E22.

Sukocheva OA, Li B, Due SL, et al. Androgens and esophageal cancer: What do we know? World J Gastroenterol. 2015;21: 6146–6156.

Mello AA, Leal MF, Rey JA, et al. Deregulated Expression of SRC, LYN and CKB Kinases by DNA Methylation and Its Potential Role in Gastric Cancer Invasiveness and Metastasis PLoS ONE 2015;10:e0140492.

Guo H, Zhang G, Mai R. Alcohol dehydrogenase-1B Arg47His polymorphism and upper aerodigestive tract cancer risk: a meta-analysis including 24,252 subjects. Alcohol Clin Exp Res. 2012;36:272-8.

Crnic I, Strittmatter K, Cavallaro U, et al. Loss of neural cell adhesion molecule induces tumor metastasis by up-regulating lymphangiogenesis. Cancer Res. 2004;64:8630-8.

Barrett CW, Ning W, Chen X, et al. Tumor suppressor function of the plasma glutathione peroxidase Gpx3 in colitis-associated carcinoma. Cancer Res. 2013; 73:1245–1255.

Zhao H, Li J, Li X, et al. Silencing GPX3 Expression Promotes Tumor Metastasis in Human Thyroid Cancer. Curr Protein Pept Sci. 2015;16:316 − 21.

Liu J, Liu Z, Liu Q, et al. CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma. Oncol Rep. 2018;40:2023–2035.

Chen H, Li H, Zhao J, et al. High intratumoral expression of tetranectin associates with poor prognosis of patients with gastric cancer after gastrectomy. J Cancer. 2017;8:3623–3630.

Afshar-Kharghan V. The role of the complement system in cancer. J Clin Invest. 2017;127:780–789.

Reis ES, Mastellos DC, Ricklin D, et al. Complement in cancer: untangling an intricate relationsship. Nat Rev Immunol. 2018;18:5–18.

Chen C, Chiou S, Yang C, et al. Secreted gelsolin desensitizes and induces apoptosis of infiltrated lymphocytes in prostate cancer. Oncotarget 2017;8: 77152–77167.

Kim JC, Ha YJ, Tak KH, et al. Opposite functions of GSN and OAS2 on colorectal cancer metastasis, mediating perineural and lymphovascular invasion, respectively. PLoS One. 2018;13(8):e0202856.

Li Q, Shi L, Gui B, et al. Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14. Cancer Res 2011;71:6899–6908.

Zhang X, Wan J, Ke Z, et al. TMEM88, CCL14 and CLEC3B as prognostic biomarkers for prognosis and palindromia of human hepatocellular carcinoma. Tumour Biol. 2017;39:1–9.

Esau L, Sagar S, Bangarusamy D et al. Identification of CETP as a molecular target for estrogen positive breast cancer cell death by cholesterol depleting agents. Genes Cancer 2016;7:309–322.

Lee IH, Sohn M, Lim HJ, Yoon S, Oh H, Shin S, et al. Ahnak functions as a tumor suppressor via modulation of TGFbeta/Smad signaling pathway. Oncogene. 2014;33:4675–84.

SupplementaryTables.pdf

Download PDF

Journal Publication

published 07 Apr, 2021

Read the published version in Scientific Reports →

Editorial decision: Major revision
27 Jan, 2021
Reviews received at journal
25 Jan, 2021
Reviewers agreed at journal
24 Jan, 2021
Reviewers agreed at journal
24 Jan, 2021
Reviews received at journal
24 Jan, 2021
Reviewers agreed at journal
24 Jan, 2021
Reviewers agreed at journal
24 Jan, 2021
Reviewers invited by journal
21 Jan, 2021
Editor assigned by journal
21 Jan, 2021
Editor invited by journal
08 Dec, 2020
Submission checks completed at journal
08 Dec, 2020
First submitted to journal
04 Dec, 2020

You are reading this latest preprint version

Characterization of Leading Dysregulated Plasma-Proteome Associated Genes in Patients with Gastro-Esophageal Cancers.

Status:

Journal Publication

Version 1

Abstract

Figures

Introduction

Methods

TCGA Gene expression Analyses

Results

Discussion

Declarations

References

Supplementary Files

Status:

Journal Publication

Version 1